Financial Summary (All financials)
| In millions, except per share items | Jan-28-23 | Jan-29-22 | Jan-30-21 | Feb-01-20 | Feb-02-19 | Feb-03-18 | Jan-28-17 | Jan-30-16 |
| Revenues | 109,120.0 | 106,005.0 | 93,561.0 | 78,112.0 | 75,356.0 | 72,714.0 | 70,271.0 | 73,785.0 |
| Revenue growth | 2.9% | 13.3% | 19.8% | 3.7% | 3.6% | 3.5% | -4.8% | 1.6% |
| Cost of goods sold | 82,229.0 | 74,963.0 | 66,177.0 | 54,864.0 | 53,299.0 | 51,125.0 | 49,145.0 | 52,241.0 |
| Gross profit | 26,891.0 | 31,042.0 | 27,384.0 | 23,248.0 | 22,057.0 | 21,589.0 | 21,126.0 | 21,544.0 |
| Gross margin | 24.6% | 29.3% | 29.3% | 29.8% | 29.3% | 29.7% | 30.1% | 29.2% |
| Selling, general and administrative | 20,658.0 | 19,752.0 | 18,615.0 | 16,233.0 | 15,723.0 | 15,140.0 | 14,217.0 | 14,665.0 |
| EBITA | 3,848.0 | 8,946.0 | 6,539.0 | 4,658.0 | 4,124.0 | 4,238.0 | 4,877.0 | 4,968.0 |
| EBITA margin | 3.5% | 8.4% | 7.0% | 6.0% | 5.5% | 5.8% | 6.9% | 6.7% |
| Amortization of intangibles | | | | | 14.0 | 14.0 | 13.0 | 23.0 |
| EBIT | 3,848.0 | 8,946.0 | 6,539.0 | 4,658.0 | 4,110.0 | 4,224.0 | 4,864.0 | 4,945.0 |
| EBIT margin | 3.5% | 8.4% | 7.0% | 6.0% | 5.5% | 5.8% | 6.9% | 6.7% |
| Pre-tax income | 3,418.0 | 8,907.0 | 5,546.0 | 4,190.0 | 3,676.0 | 3,630.0 | 3,961.0 | 4,923.0 |
| Income taxes | 638.0 | 1,961.0 | 1,178.0 | 921.0 | 746.0 | 722.0 | 1,295.0 | 1,602.0 |
| Tax rate | 18.7% | 22.0% | 21.2% | 22.0% | 20.3% | 19.9% | 32.7% | 32.5% |
| Earnings from continuing ops | 2,780.0 | 6,946.0 | 4,368.0 | 3,281.0 | 2,937.0 | 2,914.0 | 2,734.0 | 3,363.0 |
| Earnings from discontinued ops | | | | | | 0.0 | | |
| Net income | 2,780.0 | 6,946.0 | 4,368.0 | 3,281.0 | 2,937.0 | 2,914.0 | 2,734.0 | 3,363.0 |
| Net margin | 2.5% | 6.6% | 4.7% | 4.2% | 3.9% | 4.0% | 3.9% | 4.6% |
| |
| Diluted EPS | $5.98 | $14.10 | $8.64 | $6.36 | $5.51 | $5.30 | $4.69 | $5.31 |
| Shares outstanding (diluted) | 464.7 | 492.7 | 505.4 | 515.6 | 533.2 | 550.3 | 582.5 | 632.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|